Hiroshi Murata
Kumamoto University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hiroshi Murata.
Gastroenterologia Japonica | 1991
Masaomi Nakashima; Ken Yoshida; Kiyonori Izuno; Hiroshi Murata; Shigetoshi Fujiyama; Tatsuo Sato
SummaryEndoscopic injection sclerotherapy (EIS) for rupture of esophageal varices was carried out in 13 patients of liver cirrhosis with hepatocellular carcinoma (HCC). Sclerotherapy was performed by intravariceal injections of 5% ethanolamine oleate. According to the manual for the staging of cancer, these HCCs were classified as Stage I in 1 case, II in 1 case, III in 2 cases, and IV in 9 cases. There was no difference between post EIS prognosis and stage. Child’s classification of these patients were class A in 1 case, B in 5 cases, and C in the remaining 7 cases. Only in 1 case of Child’s A and 1 case of Child’s B who were less advanced clinically and were free from icterus and ascites did EIS produce favorable results, it arresting esophageal variceal hemorrhage and led to a relatively good outcome. We suggest that emergency EIS for rupture of esophageal varices should be performed in patients with relatively good general conditions, irrespective of the stage of HCC.
Gastroenterologia Japonica | 1991
Shin-ichi Kawano; Shigetoshi Fujiyama; Shinjiro Sato; Ken Yoshida; Junji Shibata; Hiroshi Murata; Tetsuo Kawahara; Kyosuke Mizuno; Saneo Nonaka; Tatsuo Sato
SummaryIn 1989, the Chiron group developed an enzyme immunoassay system (C100) for detecting antibodies to hepatitis C virus (anti-HCV). In our examinations, the postivie rate was 65.3% of the total number of patients (199) with non-A, non-B (NANB) liver disease. Additionally, a specific ELISA system (KCL-163) was developed by Kaketsuken (Kumamoto, Japan) based on synthetic peptides corresponding to an HCV genome of a Japanese isolate. In this study, we measured antibodies to HCV by KCL-163, and compaired the results of KCL-163 with that of C100 in patients with various liver diseases. Our emphasis was on the discrepancies between the results of the two types of ELISA. We concluded that it was not sufficient to diagnose hepatitis C only by assay systems based on the C100-3 region of an HCV genome, and that KCL-163 was superior to C100 in its specificity and sensitivity in the diagnosis of hepatitis C.
Digestive Endoscopy | 2001
Sebastião Mitsuji Miyazaki; Mimian Graciela Matsuda; Atsunobu Misumi; Ubehiko Honmyo; Akitoshi Murakami; Hiroshi Murata; Katsuro Sagara; Ryouichi Kurano; Hiroaki Okabe
We used a Mongolian gerbil model to evaluate the effects of long‐term Helicobacter pylori infection on blood flow, gastric acidity and atrophic change of the gastric mucosa.
International Journal of Hematology | 1995
Hiromitsu Matsuzaki; Hiroyuki Hata; Takashi Sonoki; Fumihiko Matsuno; Noriomi Kuribayashi; Minoru Yoshida; Akitoshi Nagasaki; Hiroshi Murata; Shigetoshi Fujiyama; Kiyoshi Takatsuki
Kanzo | 1992
Hideto Chikazawa; Shigetoshi Fujiyama; Kiyonori Izuno; Shin-ichi Kawano; Hiroshi Murata; Junji Shibata; Tatsuo Sato
Kanzo | 2007
Hitoshi Takeuchi; Takashi Arata; Kiyoto Takehara; Kunitoshi Shigeyasu; Takashi Kanazawa; Hiroshi Murata; Hitoshi Nakagawa; Koji Tanakaya; Taichirou Kanagawa; Yasuhiro Makino; Yoshitaka Takuma; Takeyuki Ohta
Nihon Rinsho Geka Gakkai Zasshi (journal of Japan Surgical Association) | 2009
Kiyoto Takehara; Kohji Tanakaya; Kunitoshi Shigeyasu; Takashi Arata; Hiroshi Murata; Hitoshi Takeuchi
Gastroenterology | 2000
Sebastião Mitsuji Miyazaki; Atsunobu Misumi; Hiroshi Murata; Graciela Mimian Matsuda; Hiroaki Okabe
Japanese Journal of Medicine | 1990
Masatoshi Sakai; Katsuro Sagara; Shigetoshi Fujiyama; Hiroshi Murata; Tatsuo Sato
The Japanese journal of gastro-enterology | 1988
Junji Shibata; Hiroshi Murata; Shigetoshi Fujiyama; Ken Yoshida; Tatsuo Sato